Search / Trial NCT00002410

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Launched by DUPONT MERCK · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Hiv 1 Drug Therapy, Combination Zidovudine Drug Resistance, Microbial Hiv Protease Inhibitors Lamivudine Indinavir Genotype Reverse Transcriptase Inhibitors Efavirenz

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the enzyme cytochrome P-450 3A4 \[CYP3A4\] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events \[i.e., cardiac arrhythmia, prolonged sedation\]).
  • Rifampin or rifabutin (prohibited because of potential drug interaction with indinavir).
  • Ketoconazole, itraconazole, and clarithromycin.
  • Concomitant systemic therapy for acute opportunistic infection or malignancy.
  • Excluded:
  • Life expectancy less than 12 months.
  • Prior Medication:
  • Excluded:
  • Prior treatment with efavirenz, 3TC, an NNRTI, or an HIV protease inhibitor.
  • Prior antiretroviral agent within 14 days of initiating study treatment.
  • Prior treatment (within 30 days of initiating study treatment) with any other experimental drug for any indication.
  • Patients must:
  • Have a diagnosis of HIV infection.
  • Have CD4 counts greater than or equal to 50 cell/mm3.
  • Have a life expectancy greater than or equal to 12 months.
  • Be post-pubescent.

About Dupont Merck

DuPont Merck, a collaboration between two leading pharmaceutical entities, combines innovative research and development capabilities with a commitment to advancing healthcare solutions. Focused on delivering high-quality therapeutics, the organization specializes in the discovery and commercialization of novel medications across various therapeutic areas, including oncology, cardiology, and infectious diseases. With a strong emphasis on clinical trials, DuPont Merck strives to enhance patient outcomes through rigorous scientific inquiry and collaboration, ensuring that new treatments meet the highest standards of safety and efficacy.

Locations

Miami, Florida, United States

Philadelphia, Pennsylvania, United States

Augusta, Georgia, United States

New York, New York, United States

Omaha, Nebraska, United States

Washington, District Of Columbia, United States

Kansas City, Missouri, United States

Coral Gables, Florida, United States

Lexington, Kentucky, United States

Phoenix, Arizona, United States

Tucson, Arizona, United States

Vero Beach, Florida, United States

Los Angeles, California, United States

Providence, Rhode Island, United States

Houston, Texas, United States

Tampa, Florida, United States

Beverly Hills, California, United States

Irvine, California, United States

Los Angeles, California, United States

Los Angeles, California, United States

Stamford, Connecticut, United States

Bradenton, Florida, United States

Jacksonville, Florida, United States

Lake Worth, Florida, United States

Tampa, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Indianapolis, Indiana, United States

Las Vegas, Nevada, United States

New York, New York, United States

Winston Salem, North Carolina, United States

Columbus, Ohio, United States

Dallas, Texas, United States

Dallas, Texas, United States

Fort Worth, Texas, United States

Houston, Texas, United States

San Antonio, Texas, United States

Newport News, Virginia, United States

Seattle, Washington, United States

Milwaukee, Wisconsin, United States

San Juan, , Puerto Rico

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials